Ptc Therapeutics's top three insider shareholders as of May 30, 2026 are Matthew B. Klein (Chief Executive Officer, 396.92K shares), Stuart Walter Peltz (Chief Executive Officer, 221.87K shares), Michael Schmertzler (Director, 163.27K shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Michael Schmertzler | - | 163,266 | 0 | 06 Jan, 2026 |
| Eric Pauwels | Chief Business Officer | 77,122 | 0 | 20 Feb, 2026 |
| Jerome B Zeldis | - | 22,500 | 0 | 06 Jan, 2026 |
| Dawn Svoronos | - | 29,017 | 0 | 10 Jun, 2022 |
| Neil Gregory Almstead | Chief Technical Ops Officer | 60,137 | 0 | 03 Apr, 2026 |
| Mark Elliott Boulding | Exec. Vp And Clo | 105,212 | 0 | 08 Apr, 2026 |
| Stuart Walter Peltz | Chief Executive Officer | 166,962 | 54,903 | 02 Feb, 2023 |
| Allan Steven Jacobson | - | 21,451 | 0 | 06 Jan, 2026 |
| Lee Scott Golden | Evp Chief Medical Officer | 79,944 | 0 | 09 Mar, 2026 |
| Christine Marie Utter | Svp, Chief Accounting Officer | 70,199 | 0 | 20 Feb, 2026 |
| Stephanie Okey | - | 8,000 | 0 | 12 Mar, 2026 |
| Emily Luisa Hill | Chief Financial Officer | 38,925 | 0 | 29 Mar, 2023 |
| Matthew B. Klein | Chief Executive Officer | 396,920 | 0 | 13 Mar, 2026 |
| Mary L. Smith | - | 21,813 | 0 | 06 Jan, 2026 |
| Alethia Young | - | 21,067 | 0 | 06 Jan, 2026 |
| William F. Jr. Bell | - | 10,333 | 0 | 16 Feb, 2024 |
| Pierre Gravier | Chief Financial Officer | 87,318 | 0 | 20 Feb, 2026 |
| Jessica Caroline Chutter | - | 7,333 | 0 | 26 Mar, 2026 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 06 Apr, 2026 | Mark Elliott Boulding | Common Stock | A | 2,265 | $39.42 | 107,477 | D | M |
| 06 Apr, 2026 | Mark Elliott Boulding | Common Stock | D | 822 | $68.91 | 106,655 | D | S |
| 06 Apr, 2026 | Mark Elliott Boulding | Common Stock | D | 1,443 | $69.75 | 105,212 | D | S |
| 06 Apr, 2026 | Mark Elliott Boulding | Stock Option (Right to Buy) | D | 2,265 | $0.00 | 6,798 | D | M |
| 01 Apr, 2026 | Neil Gregory Almstead | Common Stock | D | 39,393 | $68.89 | 72,747 | D | S |
| 01 Apr, 2026 | Neil Gregory Almstead | Common Stock | D | 12,530 | $69.50 | 60,217 | D | S |
| 01 Apr, 2026 | Neil Gregory Almstead | Common Stock | D | 80 | $70.30 | 60,137 | D | S |
| 24 Mar, 2026 | Jessica Caroline Chutter | Common Stock | A | 4,000 | $0.00 | 4,000 | D | A |
| 24 Mar, 2026 | Jessica Caroline Chutter | Common Stock | A | 3,333 | $0.00 | 7,333 | D | A |
| 24 Mar, 2026 | Jessica Caroline Chutter | Stock Option (Right to Buy) | A | 3,475 | $0.00 | 3,475 | D | A |
| 24 Mar, 2026 | Jessica Caroline Chutter | Stock Option (Right to Buy) | A | 2,896 | $0.00 | 2,896 | D | A |
| 11 Mar, 2026 | Matthew B. Klein | Common Stock | A | 12,500 | $0.00 | 399,582 | D | A |
| 12 Mar, 2026 | Matthew B. Klein | Common Stock | D | 2,662 | $64.08 | 396,920 | D | S |
| 10 Mar, 2026 | Stephanie Okey | Common Stock | A | 1,167 | $33.63 | 9,167 | D | M |
| 10 Mar, 2026 | Stephanie Okey | Common Stock | D | 1,167 | $70.00 | 8,000 | D | S |
| 10 Mar, 2026 | Stephanie Okey | Common Stock | A | 14,000 | $33.63 | 22,000 | D | M |
| 10 Mar, 2026 | Stephanie Okey | Common Stock | D | 14,000 | $70.00 | 8,000 | D | S |
| 10 Mar, 2026 | Stephanie Okey | Stock Option (Right to Buy) | D | 1,167 | $0.00 | 0 | D | M |
| 10 Mar, 2026 | Stephanie Okey | Stock Option (Right to Buy) | D | 14,000 | $0.00 | 0 | D | M |
| 05 Mar, 2026 | Lee Scott Golden | Common Stock | D | 10,000 | $63.38 | 79,944 | D | S |